Johnson & Johnson Q3: Talc Resolution Offer Impacts Earnings, MedTech Slows Growth (JNJ)
· seekingalpha.com
Johnson & Johnson Q3 2026: revenue up 6%, but EPS fell, and shares slid 5% amid a $5.5B talc reserve. Click for this JNJ earnings update and see if it is right for you.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and ...